Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01740284
Other study ID # GT-19
Secondary ID
Status Completed
Phase Phase 3
First received November 14, 2012
Last updated February 7, 2013
Start date September 2008
Est. completion date January 2009

Study information

Verified date February 2013
Source ALK-Abelló A/S
Contact n/a
Is FDA regulated No
Health authority Germany: Paul-Ehrlich-Institut
Study type Interventional

Clinical Trial Summary

Many grass pollen allergic subjects treated with immunotherapy tablets experience treatment related adverse events when initiating treatment.

The majority are local allergic reactions within the mouth and/or throat, and most of these reactions are mild or moderate. It is anticipated that intake of antihistamine before initiation of Grazax treatment would most likely reduce the discomfort associated with initiation of Grazax treatment. So this trial was to investigate if administration of antihistamine prior to initiation of Grazax treatment results in a reduction of subjects reporting local allergic reactions.


Description:

Many grass pollen allergic subjects treated with immunotherapy tablets experience treatment related adverse events when initiating treatment. The adverse events are considered consistent with the introduction of allergens in sensitised subjects. The majority are local allergic reactions within the mouth and/or throat. Most of these reactions are mild or moderate in intensity, have an onset almost immediately after taking a tablet, and last from minutes to hours after intake. Appearance of adverse events in relation to tablet intake tends to subside spontaneously within 1 to 7 days. Thus, initiation of treatment with Grazax may be associated with discomfort. It is anticipated that intake of antihistamine before initiation of Grazax treatment would most likely reduce the discomfort associated with initiation of Grazax treatment. Therefore, the rationale for this trial was to investigate if administration of antihistamine prior to initiation of Grazax treatment results in a reduction of subjects reporting local allergic reactions.


Recruitment information / eligibility

Status Completed
Enrollment 46
Est. completion date January 2009
Est. primary completion date January 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Male or female 18-65 years of age

- Written informed consent obtained before any clinical trial procedures are performed

- A clinical history of grass pollen induced allergic rhinoconjunctivitis of two years or more requiring treatment during the grass pollen season

- Reporting of treatment related allergic AEs (local reactions in mouth and throat) after intake of Grazax at screening (visit 1)

- Positive skin prick test (SPT) response (wheal diameter = 3 mm larger than the negative control with a flare) to Phleum pratense

- Female subjects had to be non-pregnant and non-lactating.

- Subject willing and able to comply with the protocol

Exclusion Criteria:

- Uncontrolled asthma in the past 12 months

- FEV1 < 70% of predicted value (calculated according to ECCS (20))

- A clinical history of symptomatic seasonal allergic rhinitis and/or asthma due to another allergen which might have caused symptoms during the conduct of this trial

- A clinical history of significant symptomatic perennial rhinitis or allergic rhinitis/asthma caused by an allergen to which the subject was regularly exposed

- At randomization, current symptoms of, or treatment for, upper respiratory tract infection, acute sinusitis, acute otitis media or other relevant infectious process (serous otitis media is not an exclusion criterion)

- History of emergency visit or admission for asthma in the previous 12 months

- Use of an investigational drug within 30 days prior to screening

- History of anaphylaxis, including anaphylactic food allergy, insect venom anaphylaxis, exercise anaphylaxis or drug induced anaphylaxis

- History of chronic urticaria within the last year

- History of angioedema

- Any of the following underlying conditions known or suspected to be present:

- Cystic fibrosis, malignancy, insulin-dependent diabetes, malabsorption or malnutrition, renal, or hepatic insufficiency, chronic infection, drug dependency or alcoholism

- Any evidence of disease making implementation of the protocol or interpretation of the protocol results difficult or jeopardising the safety of the subject (e.g. clinically significant cardiovascular, serious immunopathologic, immunodeficiency whether acquired or not, hepatic, neurologic, psychiatric and ongoing long term treatment with tranquilizer or psychoactive drugs, endocrine, or other major systemic disease or malignancies (including auto-immune diseases, tuberculosis and HIV)).

- Immunosuppressive treatment

- History of allergy, hypersensitivity or intolerance to IMPs (except for Phleum pratense) or desloratadine

- Unlikely to be able to complete the trial, for any reason, or likely to travel for extended periods of time during the trial, which in the opinion of the investigator will compromise the data

- Being the investigator, trial staff or their immediate families, defined as the investigator's/staff's spouse, parent, child, grandparent, or grandchild or being the 2nd member of a family (living in the same household)

- Use of any prohibited drugs

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Intervention

Drug:
Grazax + Aerius

Grazax + placebo


Locations

Country Name City State
Germany Zentrum für Rhinologie und Allergologie Wiesbaden

Sponsors (1)

Lead Sponsor Collaborator
ALK-Abelló A/S

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate whether intake of antihistamine in connection with Grazax treatment results in a reduction in number of subjects reporting treatment related AEs the first day of Grazax exposure 28 days following the first dosing Yes
Secondary Other safety endpoint Vitals signs measured three times (Day 0, Day 14 and Day 28) 28 days following first dosing Yes
Secondary Other safety endpoint FEV1 measured three times (Day 0, Day 14 and Day 28) 28 Days following the first dosing Yes
See also
  Status Clinical Trial Phase
Completed NCT03850626 - Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
Completed NCT03682965 - Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study Phase 2
Completed NCT04541004 - Adolescent Mite Allergy Safety Evaluation Phase 3
Completed NCT02556801 - Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy Phase 2
Completed NCT01966224 - A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects Phase 1
Completed NCT01918956 - PURETHAL Birch RUSH Study Phase 4
Completed NCT01682070 - SUBLIVAC FIX Phleum Pratense DT/DRF Phase 2
Completed NCT01438827 - Avanz Phleum Pratense Maintenance Dose Phase 2/Phase 3
Completed NCT01438463 - PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis Phase 2
Completed NCT02437786 - Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® Phase 4
Completed NCT00985296 - Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC) N/A
Completed NCT04912076 - S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen Phase 1
Completed NCT03365648 - Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics N/A
Completed NCT05455749 - Effect of holoBLG on Cat Allergic Patients N/A
Completed NCT01707069 - A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Phase 1
Completed NCT01567306 - Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense Phase 2
Completed NCT01466465 - Vitamin D and Grass Pollen Specific Immunotherapy Phase 2
Completed NCT01490411 - Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis Phase 2
Completed NCT00777374 - Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration Phase 2
Active, not recruiting NCT04502966 - Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction Phase 2